NCT02060201View on ClinicalTrials.gov

Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)

PHASE1CompletedINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Saxagliptin

DRUG

Dapagliflozin

DRUG

Saxagliptin/Dapagliflozin FDC

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY